Compare PODD & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PODD | HOLX |
|---|---|---|
| Founded | 2000 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 16.6B |
| IPO Year | 2007 | 1995 |
| Metric | PODD | HOLX |
|---|---|---|
| Price | $239.59 | $75.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 13 |
| Target Price | ★ $358.00 | $77.89 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 05-20-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.48 | 0.79 |
| Revenue | $2,708,100,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | $24.33 | $4.74 |
| Revenue Next Year | $19.33 | $5.03 |
| P/E Ratio | ★ $70.10 | $95.77 |
| Revenue Growth | ★ 30.73 | 1.74 |
| 52 Week Low | $230.08 | $51.90 |
| 52 Week High | $354.88 | $75.69 |
| Indicator | PODD | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.81 | 65.62 |
| Support Level | $238.68 | $74.53 |
| Resistance Level | $299.75 | N/A |
| Average True Range (ATR) | 8.49 | 0.22 |
| MACD | 0.71 | 0.03 |
| Stochastic Oscillator | 7.18 | 90.79 |
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.